Article
Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
Cancer medicine - 1 Sept 2022
Mitiushkina Natalia V, Romanko Alexandr A, Preobrazhenskaya Elena V, Tiurin Vladislav I, Ermachenkova Tatiana I, Martianov Alexandr S, Mulkidjan Rimma S, Sokolova Tatiana N, Kholmatov Maksim M, Bizin Ilya V, Ivantsov Alexandr O, Yatsuk Olga S, Zaitseva Olga A, Iyevleva Aglaya G, Kuligina Ekatherina Sh, Imyanitov Evgeny N
Abstract excerpt
BACKGROUND: Despite the progress in the development of next-generation sequencing (NGS), diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low cost. Tests for 5'-/3'-end mRNA unbalanced expression can be used for variant-independent detection of translocations, however, many technical aspects of this methodology require additional investigations. METHODS: Known ALK/ROS1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.